Exec Chat: PFA, Patient Monitoring, Modular CRM Open Opportunities For Boston Scientific
In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.
You may also be interested in...
JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.
Cardio Catch-Up: Arga, HeartPoint Plan First-In-Human Trials Of Novel Devices; Medtronic And Edwards Announce Product Launches, And More
The second half of summer is usually a slow time for news about cardiac technology innovations because there are not many major conferences. But there was still plenty of innovation news coming from both small and big cardiovascular device companies in July and August.
After announcing that its estimated second-quarter 2022 revenue exceeded analysts’ expectations, Acutus announced that David Roman, the interim CEO and CFO, is now the permanent CEO. Also, Steven Mickelsen announced that he is stepping down as Acutus’ chief translational science officer.